Martin L Sos

Martin L Sos

UNVERIFIED PROFILE

Are you Martin L Sos?   Register this Author

Register author
Martin L Sos

Martin L Sos

Publications by authors named "Martin L Sos"

Are you Martin L Sos?   Register this Author

44Publications

1818Reads

47Profile Views

Family matters: How MYC family oncogenes impact small cell lung cancer.

Cell Cycle 2017 Aug 24;16(16):1489-1498. Epub 2017 Jul 24.

a Molecular Pathology, Institute of Pathology, University of Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2017.1339849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584863PMC
August 2017

Resistance Mechanisms to AZD9291 and Rociletinib-Response.

Clin Cancer Res 2017 07;23(14):3967-3968

Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0948DOI Listing
July 2017

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

J Thorac Oncol 2015 Jul;10(7):1049-57

*Institute of Pathology, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Cologne/Bonn, University Hospital of Cologne, Cologne, Germany; ‡Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; §Labor Dr. Quade und Kollegen GmbH, Cologne, Germany; ‖Institute of Human Genetics, University of Cologne, Cologne, Germany; ¶Targos Molecular Pathology GmbH, Kassel, Germany; #Department of Translational Genomics, University of Cologne, Cologne, Germany; **Cologne Center for Genomics, Cologne, Germany; ††GENterprise GENOMICS GmbH, Mainz, Germany; ‡‡Bristol-Myers Squibb R&D, Princeton, New Jersey; §§Evangelische Kliniken Johanniter, Bonn, Germany; ‖‖Malteser Krankenhaus, Lung Cancer Center, Bonn, Germany; ¶¶Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; ##Institute for Hematopathology Hamburg, Hamburg, Germany; and ***New Oncology, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000570DOI Listing
July 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

J Thorac Oncol 2015 Jun;10(6):e40-3

*Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; †Center for Integrated Oncology Köln Bonn, Institute of Pathology, University Hospital of Cologne, Cologne, Germany; ‡Department of Translational Genomics, Center for Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany; §Lung Cancer Group Cologne, Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ‖Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; ¶Center for Integrated Oncology Köln Bonn, Institute of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and #Institute of Hematopathology Hamburg, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000503DOI Listing
June 2015

Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Clin Cancer Res 2015 May;21(10):2236-43

Department of Medicine (Medical Oncology) and Pathology, University of Colorado Denver, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862209PMC
May 2015

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.

Cell Rep 2014 Aug 7;8(4):1037-48. Epub 2014 Aug 7.

Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.07.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294625PMC
August 2014

Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology.

J Am Chem Soc 2013 Dec 20;135(48):18153-9. Epub 2013 Nov 20.

Howard Hughes Medical Institute and Department of Cellular & Molecular Pharmacology, University of California , San Francisco, California 94143, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ja408704uDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938282PMC
December 2013

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Nature 2013 Nov 20;503(7477):548-51. Epub 2013 Nov 20.

1] Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, California 94158, USA [2].

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nature12796
Publisher Site
http://dx.doi.org/10.1038/nature12796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274051PMC
November 2013

A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Cell 2013 Aug;154(4):737-47

Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2013.07.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950538PMC
August 2013

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

J Med Chem 2013 Jul 10;56(14):5757-72. Epub 2013 Jul 10.

Department of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Strasse 6, D-44227 Dortmund, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm4004076DOI Listing
July 2013

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Nat Genet 2012 Oct 2;44(10):1104-10. Epub 2012 Sep 2.

Department of Translational Genomics, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915822PMC
October 2012

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Clin Cancer Res 2012 Sep 21;18(17):4682-90. Epub 2012 Aug 21.

Department of Translational Genomics, University of Cologne, c/o MPI for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3260DOI Listing
September 2012

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Clin Cancer Res 2011 Dec 26;17(23):7394-401. Epub 2011 Sep 26.

Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382103PMC
December 2011

Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.

Bioorg Med Chem 2011 Jan 10;19(1):429-39. Epub 2010 Nov 10.

Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2010.11.007DOI Listing
January 2011

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.

PLoS One 2010 Jan 27;5(1):e8919. Epub 2010 Jan 27.

Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Max Planck Society, Köln, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008919PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811738PMC
January 2010

Systematically linking drug susceptibility to cancer genome aberrations.

Cell Cycle 2009 Nov 27;8(22):3652-6. Epub 2009 Nov 27.

Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.8.22.9936
Publisher Site
http://dx.doi.org/10.4161/cc.8.22.9936DOI Listing
November 2009

Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.

Clin Cancer Res 2005 Nov;11(22):8186-94

Molecular Tumor Biology and Tumor Immunology, Department I for Internal Medicine, Center for Molecular Medicine Cologne, University of Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0224DOI Listing
November 2005